Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro

被引:28
作者
Budman, DR
Calabro, A
Wang, LG
Liu, XM
Stiel, L
Adams, LM
Kreis, W
机构
[1] NYU, Sch Med, N Shore Univ Hosp, Dept Med,Don Monti Div Oncol, Manhasset, NY 11030 USA
[2] Glaxo Wellcome Inc, Res & Dev, Clin Applicat Res, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.3109/07357900009012201
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Empiric combinations of vinca alkaloids with taxanes have been recently used in clinical oncology. To enhance the activity of these two classes of agents, we evaluated the sequence and duration of exposure, looking for synergistic effects. Cell lines DU 145, PC 3, LnCaP, LL 86, MCF(7)wt, and MCF7/ADR (NCI/ADR-RES) were incubated with varying concentrations of paclitaxel or vinorelbine. Cytotoxicity was evaluated by a semiautomated MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide) method. Synergism or antagonism of these two agents either sequentially or in combination was determined by median effect analysis. Prolonged exposure of cells to either drug enhanced cytotoxic effect. Synergism or antagonism with vinorelbine and paclitaxel were both sequence dependent and cell line specific. In the case of MCF(7)wt, synergism was seen when a 48-hr exposure to vinorelbine preceded paclitaxel, whereas antagonism was noted when both agents were applied simultaneously or when the sequence was reversed. Concurrent vinorelbine and paclitaxel were synergistic in four of six cell lines when the exposure was extended to 96 hr but not for shorter durations of exposure. Sequential exposure of vinorelbine preceding paclitaxel or prolonged exposure to both agents concurrently needs to be tested clinically to determine whether the antitumor activity of this combination can be enhanced. In addition, these studies suggest concurrent administration of these two agents may lead to a less than optimal cytotoxic result.
引用
收藏
页码:695 / 701
页数:7
相关论文
共 46 条
  • [1] Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer
    Acuña, LR
    Langhi, M
    Pérez, J
    Acuña, JR
    Machiavelli, M
    Lacava, J
    Vallejo, C
    Romero, A
    Fasce, H
    Ortiz, E
    Grasso, S
    Amato, S
    Rodríguez, R
    Barbieri, M
    Leone, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 74 - 81
  • [2] ADAMS DJ, 1994, P AM ASSOC CANC RES, V35, pA1944
  • [3] Blagosklonny MV, 1997, CANCER RES, V57, P130
  • [4] BUDMAN DR, 1992, SEMIN ONCOL, V19, P639
  • [5] BUDMAN DR, 1996, P AM ASSOC CANC RES, V37, pA2493
  • [6] BUDMAN DR, 1996, CHEMOTHERAPY SOURCEB, P479
  • [7] CAHAN MA, 1994, CANCER CHEMOTH PHARM, V33, P441, DOI 10.1007/BF00686276
  • [8] CHANG A, 1996, P AM ASSOC CANC RES, V37, pA1158
  • [9] Chang AY, 1996, SEMIN ONCOL, V23, P19
  • [10] CHANG AY, 1995, SEMIN ONCOL, V22, P66